Biomarin Pharmaceutical Inc
XBER:BM8
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Biomarin Pharmaceutical Inc
XBER:BM8
|
US |
|
Humacyte Inc
NASDAQ:HUMA
|
US |
|
A
|
Amazon.com Inc
MIL:AMZN
|
US |
|
Coface SA
OTC:COFAF
|
FR |
|
Old Mutual Ltd
OTC:ODMUF
|
ZA |
|
M
|
Medline Inc
NASDAQ:MDLN
|
US |
|
Repay Holdings Corp
NASDAQ:RPAY
|
US |
|
Entravision Communications Corp
NYSE:EVC
|
US |
|
Tractor Supply Co
NASDAQ:TSCO
|
US |
|
DSM-Firmenich AG
OTC:DSFIY
|
CH |
|
B
|
Brookfield Asset Management Inc
TSX:BAM.A
|
CA |
|
Roche Holding AG
F:RHO5
|
CH |
Wall St Price Targets
BM8 Price Targets Summary
Biomarin Pharmaceutical Inc
According to Wall Street analysts, the average 1-year price target for BM8 is 81.48 EUR with a low forecast of 45.26 EUR and a high forecast of 112.92 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is BM8's stock price target?
Price Target
81.48
EUR
According to Wall Street analysts, the average 1-year price target for BM8 is 81.48 EUR with a low forecast of 45.26 EUR and a high forecast of 112.92 EUR.
What is the Revenue forecast for Biomarin Pharmaceutical Inc?
Projected CAGR
8%
Over the last 13 years, the compound annual growth rate for Revenue has been 15%. The projected CAGR for the next 8 years is 8%.
What is the Operating Income forecast for Biomarin Pharmaceutical Inc?
Projected CAGR
14%
The compound annual growth rate for Operating Income over the next 8 years is 14%.
What is the Net Income forecast for Biomarin Pharmaceutical Inc?
Projected CAGR
23%
The compound annual growth rate for Net Income over the next 8 years is 23%.
